- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL2009 | First Faculty of Medicine
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting2006 | First Faculty of Medicine
- A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting2006 | Faculty of Physical Education and Sport
- A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis2006 | First Faculty of Medicine
- Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program2021 | First Faculty of Medicine
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosis2007 | First Faculty of Medicine
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosis2007 | Faculty of Physical Education and Sport
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis2010 | Second Faculty of Medicine
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis2015 | First Faculty of Medicine
- The effects of natalizumab on a test of cognitive function in patients with relapsing multiple sclerosis (MS)Publication without faculty affiliation
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis2012 | Second Faculty of Medicine
- Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study2022 | Faculty of Medicine in Hradec Králové
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine
- Comparison of switch to fingolimod and continued treatment with glatiramer acetate or interferon Beta in patients with relapsing multiple sclerosis: Follow-up analysis of the EPOC clinical trial2015 | Publication without faculty affiliation
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial2021 | First Faculty of Medicine
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study2023 | First Faculty of Medicine
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | First Faculty of Medicine, Second Faculty of Medicine
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a2018 | First Faculty of Medicine
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial2022 | First Faculty of Medicine
- Clinical results from AFFIRM: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of Natalizumab in patients with relapsing multiple sclerosisPublication without faculty affiliation
- The incidence and significance of anti-natalizumab antibodies - Results from AFFIRM and SENTINEL2007 | Second Faculty of Medicine
- Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence2023 | First Faculty of Medicine
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | First Faculty of Medicine
- Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies2023 | First Faculty of Medicine
- Treatment of multiple sclerosis with oral cladribine: results of clinical trials2017 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: WA21092Publication without faculty affiliation